|Bid||53.55 x 1200|
|Ask||53.85 x 800|
|Day's Range||53.46 - 54.07|
|52 Week Range||36.15 - 57.44|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||93.00|
|Forward Dividend & Yield||1.40 (2.60%)|
|Ex-Dividend Date||Feb 27, 2020|
|1y Target Est||55.27|
BMY vs. AZN: Which Stock Is the Better Value Option?
Moderna Inc said in May that its vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, though doubts remain over whether the data is predictive of real-life success. China's military on Monday was cleared to use the COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy. U.S. company Inovio Pharmaceuticals said on Tuesday its experimental coronavirus vaccine induced immune responses in healthy volunteers and was shown to be safe in an early-stage trial.
Moderna (NASDAQ: MRNA) was the first to begin human trials of a coronavirus vaccine back in March. The clinical-stage biotech company delighted investors when it announced encouraging data from phase 1, quickly moved on to phase 2, and promised to start phase 3 in July. While Moderna remains a front-runner in the race to develop a vaccine for COVID-19, the illness caused by the novel coronavirus, the company has fallen into the shadow of big pharma.
The Food and Drug Administration (FDA) issued new rules on Tuesday for the companies developing COVID-19 vaccines. "While the FDA is committed to help expedite this work, we will not cut corners in our decision making, and we're making clear in our guidance what are the data that we need, that should be submitted, to meet our regulatory standards of approval," FDA commissioner Dr. Stephen Hahn said Tuesday during a Senate committee hearing. The guidance states that the primary efficacy endpoint in a placebo-controlled efficacy clinical trial should be at least 50%, meaning the vaccine needs "to reduce the risk of disease caused by COVID-19 by 50%" when compared to the placebo, according to Brad Loncar, a longtime biotech investor and CEO of Loncar Investments. There are a number of drugmakers developing COVID-19 vaccine candidates including AstraZeneca and the University of Oxford, Inovio Pharmaceuticals Inc. , and Moderna Inc. , two of which (Inovio and Moderna) have disclosed preliminary data from their Phase 1 trials. A return to economic normalcy has largely been tied to the arrival of vaccines that can prevent infections from the coronavirus. "There is no guarantee...that we will have a safe and effective vaccine, but we are cautiously optimistic," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, testified during the same hearing.
The U.S. Food and Drug Administration plans to release guidance on Tuesday outlining its conditions for approving a vaccine for the coronavirus, the Wall Street Journal reported, citing a summary of the guidance. The agency would require drugmakers to show "clearly demonstrated" proof of a vaccine's safety and effectiveness through a clinical study, and at least 50% more effectiveness than a placebo, the report https://www.wsj.com/articles/fda-to-issue-guidance-on-covid-19-vaccine-approval-11593516090 said. More than 100 vaccines are being tested worldwide against the virus, with only a handful in the human testing phase, including candidates from AstraZeneca Plc and Moderna Inc.
The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. Canada published the final regulations in August last year, despite strong opposition from drug companies.
Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
Brazil's Sao Paulo state expects this week to receive federal regulator approval to trial a potential coronavirus vaccine developed by China's Sinovac , governor Joao Doria said on Monday. The trial would be carried out by the Instituto Butantan, a research center funded by the state of Sao Paulo. The announcement comes as Brazil's federal government announced over the weekend that it had signed an agreement to produce another potential vaccine, developed by pharmaceutical company AstraZeneca with researchers at Oxford University.
AstraZeneca Plc (AZN) has signed a $127 million deal with Brazil for the production of its potential COVID-19 vaccine.Under the terms of the agreement, Brazil will start to locally manufacture AstraZeneca’s experimental vaccine. Elcio Franco, Brazil’s No.2 public health official, said in a press conference that the country will initially produce some 30 million doses of the investigational vaccine, half by December and half by January of next year, Reuters reported.The vaccine will be manufactured by Brazil’s Fundação Osvaldo Cruz, also known as Fiocruz, the country’s leading public health organization, Franco said.Brazil is the world’s second most affected country by the coronavirus pandemic, with more than 1.2 million confirmed cases as of Friday and more than 55,000 deaths.AstraZeneca said this month that it signed supply chain agreements for the capacity to produce 2 billion doses of its potential coronavirus vaccine, also known as AZD1222, which it is developing with Oxford University. The British drugmaker has already inked supply deals with the U.S. and European Union countries.AZD1222, is among a list of several candidates supported by Operation Warp Speed (OWS), the U.S. government program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines available for Americans by Jan. 2021.AstraZeneca shares have jumped by almost 40% since mid-March as the company joined the list of companies engaged in the development of a potential coronavirus vaccine. The stock fell less than 1% to close at $52.70 on Friday.Five-star analyst Steve Scala at Cowen & Co. earlier this month raised the drugmaker's price target to $60 from $55 and maintained a Buy rating on the shares to reflect its potential to compound annual sales at 10% and 18% through 2025.Overall AstraZeneca scores a Strong Buy consensus from the analyst community based on 4 unanimous Buy ratings. Despite the recent rally, the $61.67 average price target still puts the upside potential at 17% in the coming 12 months. (See AstraZeneca stock analysis on TipRanks).Related News: Vaxart Explodes 96%- And Rallies After-Hours- On Covid-19 Deal LabCorp Launches Neutralizing Antibody Test For Covid-19 Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million More recent articles from Smarter Analyst: * Google Snaps Up Canadian Smart Glasses Startup North * AMC Delays Theatre Openings; Top Analyst Cuts Price Target * Inovio Presents ‘Positive’ Early Data For Covid-19 Vaccine Candidate; Shares Plunge 12% * Wells Fargo Plans To Cut Its Dividend In Q3; Top Analyst Lowers Price Target
Fears of a second coronavirus wave have mounted in recent days as a number of countries have reported rising case numbers, putting stocks under pressure.
Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic. The AstraZeneca vaccine is considered the world's leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organization. Elcio Franco, Brazil's No.2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year.
Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.
AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday. The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford. This week, AstraZeneca signed its tenth supply-and-manufacturing deal.
Astrazeneca's COVID-19 vaccine candidate is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's chief scientist said on Friday. The WHO is in talks with multiple Chinese manufacturers, including Sinovac, on potential vaccines, she said.
Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan. The discussion follows a flurry of supply deals signed by the British drug maker for its experimental COVID-19 vaccine as it ramps up efforts for wider trials of the potential treatment. Daiichi Sankyo said in a statement on Friday that one of its subsidiaries would receive undiluted solution of the vaccine and then carry out formulation procedures, packaging, and storage in Japan.
From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: TSM) is a great stock.Inseego Corp (NASDAQ: INSG) is a 5G company that Cramer likes and he is sticking by it.Agenus Inc (NASDAQ: AGEN) is a momentum play and it is not doing anything, said Cramer. He would like to hear some big news from the company.Instead of Eldorado Resorts Inc (NASDAQ: ERI), Cramer would buy Penn National Gaming, Inc (NASDAQ: PENN).Cramer is a buyer of AstraZeneca plc (NYSE: AZN). He thinks it is a well-run company with some great franchises.Halliburton Company (NYSE: HAL) should be sold, believes Cramer.Alaska Air Group, Inc. (NYSE: ALK) is a very well-run airline, but Cramer would rather buy Southwest Airlines Co (NYSE: LUV) because it is the best run airline.See more from Benzinga * Cramer Shares His Thoughts On Marriott, Tegna And More * Cramer Shares His Thoughts On VectoIQ, Yext And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Oxford University rolled out Africa's first human trials for a potential vaccine against the new coronavirus in South Africa on Wednesday, as cases continue to rise and concerns grow over potential access to life-saving treatments. The trial, conducted with local partner University of the Witwatersrand, will consist of 2,000 volunteers from 18 to 65 years of age, including some HIV positive patients, who will be monitored for 12 months after vaccination to asses how well the vaccine guards against COVID-19. "Once 60% of the population, especially the adult population, becomes immune, we expect that effective reproductive rate to go under 1, which basically means the virus will still be around, it will still circulate, but its chain of transmission has been interrupted," said Shabir Madhi, professor of vaccinology at Wits University and leader of the trial.